Business Wire

Rapid Medical Receives FDA Breakthrough Device Designation for Vasospasm Treatment

YOKNEAM, Israel & MIAMI--(BUSINESS WIRE)--Rapid Medical, a leading developer of advanced neurovascular devices, today announced FDA breakthrough designation for its Comaneci™ embolization assist ...
Medscape

Disappointing Topline Results for Clazosentan in Aneurysmal SAH

Clazosentan failed to meet the primary endpoint of preventing clinical deterioration as a result of delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid hemorrhage (aSAH), ...
FierceBiotech

Clarimedix, Inc. Secures Investment for Proof-of-Concept Study in Cerebral Vasospasm

BOULDER, Colo., Jan. 11, 2012 /PRNewswire/ -- Clarimedix, Inc., a privately held company focused on the development of non-invasive therapeutics for the treatment of disorders associated with vascular ...
Pharmabiz

Rapid Medical’s Comaneci receives CE Mark indication to treat cerebral vasospasm

Rapid Medical, a company focused on the development of next-generation neurovascular devices, has announced CE Mark approval for the expanded indication of Comaneci to treat cerebral vasospasm.
Healio

Nicardipine prevents angiographic vasospasm after aneurysmal subarachnoid hemorrhage

Please provide your email address to receive an email when new articles are posted on . Moderate to severe angiographic vasospasm was detected more often in controls than in those given implants. At ...